Navigation Links
Vantia Therapeutics Appoints Rachel Morten as Head of Regulatory Affairs
Date:4/21/2009

and VA111913 for dysmenorrhoea, product candidates which directly target the causes of conditions that together affect many millions of people, are poorly treated and represent billion dollar markets. Vantia was spun out from Ferring Research Ltd in 2008 and its pipeline is driven by the proven small molecule drug discovery and development capabilities of that unit and Vantia's experienced management team. Vantia's strategy is to develop candidates to Phase II proof-of-concept and then commercialise through partnerships. The Company is well-funded and backed by specialist life science investors MVM Life Science Partners, SV Life Sciences and Novo A/S.

http://www.vantiatherapeutics.com.

About VA106483 and nocturia:

VA106483 is a novel small molecule drug candidate in Phase II trials to treat nocturia, a common condition that causes sufferers to wake frequently during the night in order to urinate, thus interrupting sleep. VA106483 acts directly in the collecting ducts of the kidney by binding to vasopressin 2 receptors, decreasing urine volume. Clinical data indicate that VA106483 is generally well tolerated and an effective anti-diuretic that increases urine concentration and reduces urine output.

Vantia's initial indication for VA106483 is nocturia. A Phase II clinical programme has been designed and trials are underway, with initial results expected mid 2009.

Nocturia is commonly associated with benign prostatic hypertrophy (BPH) where it is estimated to affect up to 70% of BPH patients. With estimates putting the number of BPH/nocturia sufferers at 55 million in the seven largest markets world wide, and only 10% of these believed to be receiving any kind of treatment, it is a clear area of unmet medical need and estimated to be worth in excess of US$500m per annum. This market opportunity presents only part of
'/>"/>

SOURCE Vantia Therapeutics
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... MA (PRWEB) December 18, 2014 Reports ... in the United States suffer from one or more ... asthma, or cancer. Medication can address some of these ... daily activities that many sufferers face. While implanted nerve ... and stimulate the whole nerve, which can induce side ...
(Date:12/19/2014)... contrast to traditional LED lights where the spectrum is ... LED technology to incorporate their spectra in a single ... in low proximity installations. The Valoya L-series offers high ... is up to four times longer than commonly used ... clearly higher when compared to traditional fluorescent or LED ...
(Date:12/19/2014)... December 18, 2014 With only 2 ... special on Sartorius Biohit products . The product ... pipettes, Picus Electronic Pipette Trade-in Program, and free pipette ... Safety officers around the world. They are ideal for ... features include:, ,     Full volume range of ...
(Date:12/19/2014)... -- Egenix, Inc. is pleased to announce that Lionel ... to succeed Donald Fresne ; Mr. Fresne has also ... member of the Board.  In recognition of the many contributions ... almost twenty years, the Board designated Mr. Fresne as Chairman ... a Search Committee to find a suitable replacement with Biotech ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2
... Test to Assess Genetic Risk of Thrombosis Improves, ... Associated with Batch Processing, SUNNYVALE, Calif., and ... CPHD ) and Instrumentation Laboratory (IL), a leading,clinical ... Xpert (TM),HemosIL(R) FII & FV assay as a ...
... Experts from PAREXEL,International Corporation (Nasdaq: PRXL ... present on key topics at the,Drug Information ... being held March 3 - 5, 2008. ... PAREXEL,s thought leaders, selected by the DIA ...
... ANN ARBOR, Mich., and COLUMBIA, S.C., Feb. ... Office of Research & Statistics,are pleased to ... Exchange,(SCHIEx) has been named a finalist in ... Healthcare Users Group (MS-HUG) 2008 Innovation,Awards Program. ...
Cached Biology Technology:Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 2Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 3Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 4Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market 5PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 3PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 4CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 2CareEvolution and SCHIEx Named Interoperability Finalists for 2008 Microsoft Healthcare Users Group (MS-HUG) Healthcare Innovation Awards 3
(Date:12/17/2014)... Dec. 16, 2014 Research and Markets ... of the "Global Chemical Sensor Market 2015-2019" ... http://photos.prnewswire.com/prnh/20130307/600769 One major ... demand for medical sensors in biomedical applications. Chemical ... quick and correct diagnosis during surgical procedures. The ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "Global Facial Recognition ... http://photos.prnewswire.com/prnh/20130307/600769 ... identification of individuals. Facial recognition system measures the ... nose, jaw edges, mouth, and the distance between ...
(Date:12/11/2014)... , Dec. 09, 2014 Research and ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has ... in India 2015-2019" report to their offering. ... this market is the adoption of multimodal biometric ... characteristic of an individual for verification and identification ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2
... NY, September 17, 2009Risk factors for metabolic syndrome, such ... levels, can increase a person,s healthcare costs nearly 1.6-fold, ... factor those costs rise an average of 24%, according ... Metabolic Syndrome and Related Disorders , a peer-reviewed ...
... the National Science Foundation have awarded $824,225 in competitive ... $2.8 million project to develop early warning forecast models ... Northwest beaches. Funds were awarded to the University of ... through the interagency Ecology and Oceanography of Harmful Algal ...
... friends were enjoying a glass of wine in the Mosel ... health benefits which studies attribute to the drink. During the ... are often just discarded as waste and the friends reasoned ... an even more concentrated form, and without the alcohol, shouldn,t ...
Cached Biology News:Metabolic syndrome risk factors drive significantly higher health care costs 2New project to forecast toxic algal blooms on Pacific Northwest beaches 2The wonders of wine 2The wonders of wine 3